IPO raises £7.5m for novel cancer treatment

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity IPOs

IPO raises £7.5m for novel cancer treatment

Victoria Thiele, 
Aidan Gregory
August 11, 2021 05:40 pm
London Stock Exchange, Paternoster Square, London, England, UK
D32YJC London Stock Exchange, Paternoster Square, London, England, UK | Alamy Stock Photo

BiVictriX Therapeutics plc, an emerging biotechnology company that develops new cancer therapies, began trading on London's alternative investment market (Aim) on Wednesday following its IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOsIssue 1716
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
AG
Aidan Gregory
Gift this article